ACE-031 vs MK-677

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

ACE-031 is a soluble decoy receptor fusion protein consisting of the extracellular domain of activin type IIA receptor (ActRIIA) linked to a human IgG1 Fc region, developed by Acceleron Pharma to bind and sequester myostatin, activin, and related TGF-beta superfamily ligands that negatively regulate muscle mass, with the goal of promoting muscle growth in severe wasting conditions including Duchenne muscular dystrophy. By competitively binding circulating myostatin and related ligands, ACE-031 reduces signaling through the Smad2/3 pathway that suppresses muscle satellite cell activation and protein synthesis; in preclinical models of myopathy, blockade of ActRIIA signaling produced significant increases in lean mass, supporting its evaluation in Phase 2 human trials. A Phase 2 randomized placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy demonstrated significant increases in lean body mass; however, the trial was halted early due to vascular-related adverse events including epistaxis and telangiectasias, attributed to off-target inhibition of angiogenic TGF-beta family ligands, and the Acceleron clinical program was subsequently discontinued. ACE-031 has no FDA approval and is not approved for any indication; commercial development was halted due to the adverse event signal identified in the clinical trial; it is not commercially available, and the vascular safety concern inherent to pan-ActRIIA ligand inhibition represents an unresolved risk that precludes its extrapolation to general performance or muscle enhancement applications.

MK-677 mimics the action of ghrelin by binding to and activating the GHSR-1a receptor in the pituitary gland, stimulating pulsatile GH release. Its oral bioavailability distinguishes it from peptide-based GH secretagogues and its prolonged half-life results in sustained IGF-1 elevation. Research protocols have explored its effects on lean body mass, bone mineral density, and sleep architecture.

MK-677 (ibutamoren; ibutamoren mesylate) is an orally active, non-peptide small-molecule ghrelin receptor (GHS-R1a) agonist developed by Merck as a research compound for GH deficiency and muscle-wasting conditions, notable as one of the few GH secretagogues with confirmed oral bioavailability and a substantial human clinical dataset spanning multiple Phase 2 randomized controlled trials. MK-677 mimics ghrelin to stimulate pulsatile GH and IGF-1 secretion from the pituitary in a dose-dependent manner without directly replacing GH, and RCTs have demonstrated significant increases in fat-free mass and GH secretion in obese adults and in hemodialysis patients with nutritional deficits, establishing the pharmacology of oral GHS-R1a agonism in humans. Despite robust human pharmacological evidence, MK-677 was not advanced to FDA registration; Merck Phase 3 trials showed efficacy on surrogate endpoints but did not demonstrate the clinical outcomes required for approval, commercial development was discontinued, and no approved indication exists. MK-677 is a non-peptide research compound — not a peptide in the pharmacological sense — with no FDA approval; it is widely available through research chemical suppliers and used off-label, and considerations including its documented effects on insulin sensitivity, fasting glucose, and sustained IGF-1 elevation are relevant to its risk profile. MK-677 dosage: clinical trials studied doses of 10 mg, 25 mg, and 50 mg orally once daily. The most frequently cited research dose in the literature is 25 mg/day for body composition studies; 10 mg/day has been used in elderly populations. Administration before sleep is studied to align the GH pulse with the natural nocturnal GH peak. Unlike injectable GH secretagogues that require reconstitution, MK-677's oral route is a practical distinction — it eliminates the injection preparation process relevant to peptides requiring bacteriostatic water reconstitution. Side effects documented in RCTs include increased appetite (a direct ghrelin-mimetic effect), mild peripheral edema from water retention, and transient increases in fasting blood glucose — a clinically relevant finding for individuals with pre-existing insulin sensitivity concerns. Sustained IGF-1 elevation from long-duration use is a differentiated risk characteristic compared to short-half-life injectable GHRPs. MK-677 is sometimes grouped with performance peptides due to overlapping research contexts but is pharmacologically a non-peptide small molecule. Licensed telehealth and anti-aging providers who carry growth hormone secretagogues are listed in the PeptideBase directory.